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ABSTRACT
Mostpatientswith lungcancerhavenon-small cell lungcancer
(NSCLC) subtype and have advanced disease at the time of di-
agnosis. Improvements inboth first-lineandsubsequent ther-
apies are allowing longer survival and enhanced quality of life
for these patients. The median overall survival observed in
many second-line trials is approximately 9months, andmany
patients receive further therapy after second-line therapy.
The cytotoxic agents pemetrexed and docetaxel and the epi-
dermal growth factor receptor (EGFR) tyrosine kinase inhibi-
tors (TKIs) erlotinib and gefitinib are standard second-line
therapies. For patients with EGFR mutation, a TKI is the fa-
vored second-line therapy if not alreadyused in first-line ther-
apy. For patients without the EGFR mutation, TKIs are an
option, but many oncologists favor cytotoxic therapy. The in-
hibitorof theEML4/ALK fusionprotein, crizotinib,has recently
become a standard second-line treatment for patients with
thegenerearrangementandhaspromise forpatientswith the
ROS1 rearrangement.TheOncologist2013;18:947–953
Implications forPractice: The landscapeof first-line treatmenthasgeneratedchallenges forclinicaldecisions insecond-line ther-
apy. For the patient treated with standard chemotherapy in the first line who has a treatable molecular change, this change
should be targeted. More specifically, the patient with an epidermal growth factor receptor (EGFR) mutation should be treated
with an EGFR tyrosine kinase inhibitor, and the patient with EML4/ALK rearrangement should be treated with crizotinib. How-
ever, theseagentsare increasinglybeingused in the first line, andmostpatientsdonothave thesemolecular changes. This leaves
the clinician with many challenging questions regarding second-line therapy. How should the patient without treatable muta-
tionsbe treated?Whichclinical trials aremostpromising?Howshould thepatient treatedwitha targetedagent in the first linebe
treated in the second line? This review addresses these issues, exploring the key existing data available to help guide informed
clinical decisions.
INTRODUCTION
Lung cancer is the leading cause of cancer-relatedmortality in
the United States and in the world [1, 2]. Most patients have
the non-small cell lung cancer (NSCLC) subtype and have ad-
vanced-stage disease at the time of diagnosis. The standard
first-line therapy for advanceddisease (definedas stage IIIBor
IV) is aplatinumdoubletaloneorwitha targetedagent suchas
bevacizumab for four to six cycles [3]. Chemotherapy extends
overall survival (OS), reduces disease-related symptoms, and
improves quality of life (QoL). Historically, after completion of
four tosix cyclesofplatinum-basedtherapy,patientswereob-
served, and at the time of radiographic or clinical evidence of
disease progression, therapy was re-initiated. Approximately
30% of patients experience disease progression during first-
line chemotherapy, andall patientswith initial diseasecontrol
will eventually experience disease progression and require
subsequent therapy. The use of anticancer agents in these
clinical situations is referred to as “second-line therapy.” Cur-
rently, there are two cytotoxic agents, pemetrexed and do-
cetaxel, and two epidermal growth factor receptor (EGFR)
tyrosinekinase inhibitors (TKI), erlotinibandgefitinib, thatare
established agents in the second-line setting [4–8].
Several trials have challenged the standard of care of ob-
servation for the management of patients without progres-
sion after four cycles of platinum-based doublet first-line
chemotherapy. This strategy, referred to as “maintenance
therapy,” involves the administration of established second-
line agents immediately after successful first-line therapy, in-
stead of waiting for disease progression. Phase III trials of
erlotinib compared with placebo and pemetrexed compared
withplacebohavedemonstrated an improvement in progres-
sion-free survival (PFS) and OS with maintenance therapy [9,
10]. Maintenance therapy with pemetrexed is beneficial only
for patients with nonsquamous histology. When a mainte-
nance strategy is used as part of first-line therapy, the agent
used is typically not considered an option for second-line or
later treatment. The use of maintenance therapy has led to
reconsideration of the traditional definition of second-line
therapy.
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The use of a molecularly targeted agent in first-line
therapy can also increase the challenge of second-line ther-
apy selection.With complete testing, a drivermutation can
nowbe found formore than half of adenocarcinomas of the
lung [11–14] (Fig. 1). Both EGFR TKIs and crizotinib have
been specifically studied in second-line therapy, but both
are also approved for first-line use in patients with the rel-
evant molecular changes (EGFR mutation and ALK rear-
rangement, respectively). We will explore therapeutic
options for second-line therapy for patients treated with
targeted therapy in the first-line setting.
Docetaxel
The first agent approved for use in the second-line settingwas
docetaxel, and its approval was based on the results of two
phase III trials (Table1) [4, 6]. In the trial byShepherdetal., pa-
tientswere required to have a performance status of 0–2 and
to have received one ormore platinum-based chemotherapy
regimens [4]. Patients were randomly assigned to docetaxel
100 mg/m2 every 3 weeks or best supportive care (BSC). The
trial was amended because of excessive toxicity in the do-
cetaxel arm, and the dose of docetaxel was reduced to 75
mg/m2 every three weeks. The time to disease progression
and OS were statistically significantly longer in the docetaxel
armcomparedwith theBSCarmin the intent-to-treat (ITT)pa-
tient population. These differences were more significant in
the cohort of patients treated with 75 mg/m2 every 3 weeks.
The QoL assessments were significantly better in the do-
cetaxel armaswell,with significantdifferences in thepainand
fatigue scales [15].
A second trial compared docetaxel 100 mg/m2 or 75
mg/m2 every three weeks versus vinorelbine or ifosfamide
(selectionof theagentwasat the investigator’sdiscretion) [6].
Patients assigned to the docetaxel arm experienced a longer
PFS at 26 weeks (p  .005), but OS did not differ among the
three arms. The one-year OS rate was significantly higher in
the docetaxel 75mg/m2 arm comparedwith the control arm.
These two trials established docetaxel 75 mg/m2 as the stan-
dard second-line therapy. The clinically significant toxicities
wereneutropenia and febrile neutropenia. To reduce the rate
of these toxicities, several trials investigated a weekly com-
pared with the standard schedule of docetaxel every three
weeks. A meta-analysis using individual patient data com-
paredweekly with every three weeks docetaxel and revealed
similar OSwith both schedules [16]. Patients treatedwith do-
cetaxel weekly compared with docetaxel every three weeks
experienced a lower rate of neutropenia (5% vs. 18%; p 
.00001) and febrile neutropenia (1%vs. 6%;p .00001); no
significantdifferenceswereobserved foranemia, thrombocy-
topenia, and nonhematologic toxicities. In clinical practice,
both schedules are frequently used.
Pemetrexed
Asubsequentphase III trial comparedpemetrexed500mg/m2
every three weeks with docetaxel 75 mg/m2 every three
weeks (Table1) [7]. The trialwasdesigned todemonstrate the
non-inferiority of pemetrexed compared with docetaxel in
OS. A statistically significant difference in PFS and OS was not
observed. In the docetaxel arm compared with the pem-
etrexed arm, a higher rate of grade 3 or 4 neutropenia (40.2%
vs. 5.3%; p  .001) and febrile neutropenia (13.4% vs. 1.9%;
p .001)wasobserved. The rateofnonhematologic toxicities
was similar. This trial established pemetrexed as an alterna-
tive to docetaxel in the second-line setting.
After completion of this trial, an interaction between
pemetrexed efficacy and histology (squamous vs. nonsqua-
mous) was detected. In a retrospective subset analysis, it
was found that patients with nonsquamous histology (n 
399) experienced a superior OS with pemetrexed com-
pared with docetaxel [17]. In contrast, patients with squa-
mous histology (n  172) experienced a statistically
significantly inferior OS with pemetrexed. This trial and
other phase III trials demonstrated that the efficacy of pem-
etrexed is limited to patients with nonsquamous histology
tumors [10, 17]. Clinicians are increasing their use of pem-
etrexed in combination with a platinum agent in the first-
line setting or as single-agent maintenance therapy in
patients with nonsquamous histology. The restriction to
nonsquamous histology and the use of pemetrexed earlier
in the disease course have reduced the availability of pem-
etrexed in the second-line setting.
EGFR TKIs
The National Cancer Institute of Canada Clinical Trials Group
performed a phase III trial (BR.21) that compared erlotinib
with placebo in patients who had disease progression during
Clinicians are increasing their use of pemetrexed in
combination with a platinum agent in the first-line
setting or as single-agentmaintenance therapy in pa-
tientswithnonsquamoushistology.Therestriction to
nonsquamous histology and the use of pemetrexed
earlier in the disease course have reduced the avail-
ability of pemetrexed in the second-line setting.
Figure 1. Approximate incidence of common mutations in ade-
nocarcinoma. Numbers should be considered approximate to il-
lustrate the relative frequency of these changes as they have
never been all reported in the same series and estimates vary.
References:EGFR [11, 12],Kirsten rat sarcomaviral oncogeneho-
molog (kRAS) [12], echinoderm microtubule-associated protein-
like 4/anaplastic lymphoma kinase (EML4/ALK) [13], ROS1 [14,
15], BRAF [12], Phosphatidylinositol-4,5-Bisphosphate 3-Kinase
(PIK3CA) [12], hepatocyte growth factor receptor (MET) [12]
(note: this rate refers toMETmutation; overexpression is more
common), Human Epidermal Growth Factor Receptor 2 (HER2)
[12], Other/unknown [12].
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one or two lines of chemotherapy and who were not eligible
for further chemotherapy (Table 2). Patients assigned to the
erlotinib arm experienced a statistically significantly longer
PFS and OS than those in the BSC group [5]. Patients assigned
to the erlotinib arm also experienced a statistically signifi-
cantly longermedian time todeterioration in cough, dyspnea,
and pain, and improvement in physical function and global
QoL [18].
Gefitinib was granted accelerated approval in the United
States based on an improvement in response rate in two
phase II trials [19, 20]. A phase III trial compared gefitinibwith
placebo in patients whowere refractory or intolerant to their
previous chemotherapy (Table 2). However, a statistically sig-
nificant difference in the primary endpoint of OS was ulti-
mately not observed [21]. Based on these data, the U.S. Food
andDrug Administrationwithdrew approval for gefitinib, and
it is not commercially available in theUnited States. Following
these results, a phase III trial comparing gefitinib 250mgdaily
with docetaxel continued to enroll patients who had already
received at least one platinum-based regimen. The co-pri-
mary endpoint of the study, non-inferiority of gefitinib com-
pared with docetaxel in OS, was observed [8]. Key trials
comparing TKIs to placebo [5, 22] and to chemotheraphy
[8, 23–25] are summarized in Table 2.
Table 1. Select second-line phase III trials of cytotoxic agents
Authors Patients (n) Treatment arms Median PFS or TTP MedianOS (months) 1-year OS rate
Shepherd et al. 4 204 Docetaxel 100mg/m2 5.9 19%
Docetaxel 75mg/m2 10.6weeks 7.5 37%
BSC 6.7weeks 4.6 19%
p  .001a p .047a
Fossella et al. 6 373 Docetaxel 100mg/m2 8.4weeks 5.5 21%
Docetaxel 75mg/m2 8.5weeks 5.7 32%
Vinorelbine or ifosfamide 7.9weeks 5.6 19%
p .046 NS NS (0.025)b
Hanna et al. 7 571 Docetaxel 75mg/m2 2.9months 7.9 29.7%
Pemetrexed 500mg/m2 2.9months 8.3 29.7%
HR 0.71; p .759 HR 0.99; p .226
aDocetaxel groups combined in reported TTP, p values represent docetaxel comparedwith BSC.
bFor 1-year OS rate, comparisonwith docetaxel 100mg/m2was NS, but with docetaxel 75mg/m2, p .025.
Abbreviations: BSC, best supportive care; CI, confidence interval; HR, hazard ratio; NS, not significant; OS, overall survival; PFS, progression-free
survival; TTP: time to tumor progression.
Table 2. Select second-line phase III trials of EGFR TKIs
Authors Patients (n) Treatment arms Median PFS or TTP (months) MedianOS (months) 1-year OS rate
Shepherd et al. 5 731 Erlotinib 150mg daily 2.2 6.7 30%
Placebo 1.8 4.7 21%
HR 0.61; p .001 HR 0.70; p .001
Thatcher et al. 22 1,692 Gefitinib 250mg daily 3.0a 5.6 1.7%
Placebo 2.6 5.1 2.1%
HR 0.82; p .0006 HR 0.89; p .087
Kim et al. 8 1,433 Gefitinib 250mg daily 2.2 7.6 32%
Docetaxel 75mg/m2 2.7 8.0 34%
HR 1.04; p .47 HR 1.02; 96% CI: 0.905–1.15
Vamvakas et al. 23 297 Erlotinib 150mg daily 3.6 7.7 35.7%
Pemetrexed 500mg/m2 2.7 8.9 38.5%
p .434 HR 1.02; 96% CI: 0.905–1.15





HR 1.19; p .089 HR .96; p .73
Garassino et al. 25 229 Erlotinib 2.4 Not yet reported Not yet reported
Docetaxel 3.4
HR 0.69; p .014
aNumbers (3.0 and 2.6) represent the time to treatment failure, defined as the time from randomization to the date the patient discontinued
therapy because of an unacceptable adverse event, lack of clinical benefit, patient choice, or death.
Abbreviations: BSC, best supportive care; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival;
PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TTP, time to tumor progression.
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Second-Line Therapy for PatientsWith EGFR
Wild-TypeDisease
TheuseofEGFRmutation testing and first-line therapyhas re-
sulted in two subpopulations of patients who are eligible for
second-line therapy:patientswithEGFR-mutatedNSCLCafter
EGFRTKI therapy, andpatientswithEGFRwild-type tumors. In
contrast to the impressive results of EGFR TKI treatment for
patients with EGFR-mutated NSCLC, the results in EGFRwild-
type tumors are far more modest. Patients with EGFR wild-
type NSCLC have a response rate to EGFR TKI therapy of 1%–
7%,amedianPFSofapproximately2months,andamedianOS
of6–8months in retrospective subsetanalysesof second-line
trials [24–26]. Two recent prospective trials have demon-
strated that in the second-line setting, PFS is inferior for pa-
tients with EGFR wild-type tumors treated with erlotinib
compared with those treated with cytotoxic chemotherapy
[25, 27]. In one study, OS data are not yet available, and in the
other trial, the results were similar between erlotinib and cy-
totoxic chemotherapy. These results left a clinical need to
identifywhich patientswith EGFRwild-type tumorswill bene-
fit from EGFR TKI therapy. A recent trial, PROSE, compared
chemotherapywith erlotinib for the second-line treatment of
unselected patients with NSCLC [28]. Overall, survival was
similar in the ITT patient population. More importantly, pa-
tientswere stratified basedonVeriStrat (Biodesix, Boulder,
CO, http://www.biodesix.com/products/veristrat/) status,
a serum proteomics assay, and the trial prospectively as-
sessed the predictive capacity of VeriStrat. Among patients
with a VeriStrat “good” signature, survival was similar be-
tween chemotherapy and erlotinib. Among patients with a
VeriStrat “poor” signature, survivalwas betterwith chemo-
therapy thanwith erlotinib. Findings were similar when the
analysiswas restricted to thosewith EGFRwild-type orwith
unknown-type disease, suggesting that VeriStrat may be
able to identify patients with EGFR wild-type tumors who
should preferentially be treated with cytotoxic therapy or
who are unlikely to benefit from EGFR TKI therapy in the
second line.
Second-Line Therapy for PatientsWith an EGFR
Mutation After EGFR TKI
For those patients with an EGFRmutation who have disease
progression on an EGFR TKI, chemotherapy remains themost
often used second-line option, but a host of alternative treat-
ments seek to challenge this standard. The simplest alterna-
tive to chemotherapy alone is the addition of an EGFR TKI to
chemotherapy.Thisapproachwas initiatedbecause itwasob-
served that a portion of patients with EGFR mutation had
“flare”of their diseasewhenEGFRTKI therapywaswithdrawn
at the time of disease progression [29]. Researchers hypothe-
sized that whereas some cells were resistant to the EGFR TKI,
leading to progression, other cells remained sensitive, and
that their growth was disinhibited by withdrawal of TKI. Al-
thoughthecombinationofchemotherapyandanEGFRTKIhas
not improved treatment results in unselected populations,
[30–34] prevention of flare and ongoing suppression of resis-
tant clones might improve disease control over chemother-
apy alone in a population selected for EGFR mutation. The
treatment strategy of re-treating with a TKI after an interval
with no TKI treatment has been evaluated in two retrospec-
tive series, both of which reported clinical activity of repeat
EGFR TKI [35, 36]. In clinical practice, patients with EGFR mu-
tation who have disease progression while taking a TKI often
have progression in one or several locations, so called “oligo-
progression.” Small retrospective case series have demon-
strated the efficacy of local radiation therapy to the site(s) of
progression followed by re-initiation of EGFR TKI therapy [37,
38]. The combination of afatinib with cetuximab, a monoclo-
nal antibody against EGFR, seems promising in preliminary
data. In the first 90 evaluable patients treated in this ongoing
trial (NCT01090011), the disease control rate was 94%, the
probability of being progression-free at six months was 42%,
and the confirmed response rate was 40% (95% CI: 17–59)
[39]. Final results from this study are eagerly awaited.
EML4/ALK Rearrangements
In approximately 4% of adenocarcinomas, a gene fusion be-
tween the echinodermmicrotubule-associated protein-like 4
(EML4) and the anaplastic lymphoma kinase (ALK) gene leads
toafusiongene(EML4/ALK),whichcontributes tocarcinogen-
esis [40]. Crizotinib has been compared with chemotherapy
for second-line treatmentofpatientswith theEML4/ALKrear-
rangement. In 347 such patients randomly assigned to crizo-
tinib or chemotherapy (either docetaxel or pemetrexed),
overall response rate was superior with crizotinib (65% vs.
20%)aswasPFS(7.7monthsvs.3months;hazardratio0.49;
p .0001) [41]. Crizotinib was approved by the U.S Food and
Drug Administration in August 2011 andmay be considered a
standard second-line treatment for patients with EML4/ALK
who are treatedwith chemotherapy in the first line.
Although targeted therapy with crizotinib for patients
withEML4/ALK rearrangements certainly represents a clinical
advance, themaximumPFS thus far reported isapproximately
10 months, generating a need to define optimal subsequent
therapy [42]. For patients whose first anticancer treatment is
crizotinib, the only standard subsequent therapy is chemo-
therapy, which is typically given in the first-line setting,
namelyaplatinumdoublet,withconsiderationof theaddition
of bevacizumab in eligible patients. Two retrospective series
suggest superior treatment outcomes with pemetrexed for
patients with the EML4/ALK rearrangement [43, 44]. Heat
shock protein (HSP) inhibitors and more potent and selective
EML4/ALK inhibitors have also shown promise as additional
molecularly directed treatment options for patients with the
EML4/ALK rearrangement [45–48]. Finally, as in patientswith
the EGFR mutation who have oligoprogression on erlotinib,
retrospective data suggest the efficacy of local ablation fol-
lowed by re-treatment. In the case of EML4/ALK, this ap-
proach may be particularly promising for those with
intracranial-only progression [37].
In clinical practice, patients with EGFRmutation who
have disease progression while taking a TKI often
haveprogression inoneor several locations, so called
“oligoprogression.” Small retrospective case series
have demonstrated the efficacy of local radiation
therapy to the site(s) of progression followed by re-
initiation of EGFR TKI therapy.
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Investigational Agents
There are substantial flawswith theexisting standard second-
line agents, thus increasing the interest in experimental
agents. Docetaxel has significant toxicities and is difficult to
tolerate even as a weekly dose, pemetrexed is active only in
patients with nonsquamous histology and is frequently used
as first-line therapy, crizotinib is approved only for patients
with EML4/ALK rearrangements, and the EGFR TKIs have lim-
ited activity in patients whose tumors do not have the muta-
tion. Fewer than 20% of patients will have the actionable
changes EGFR and EML4/ALK. In contrast, kRAS is the most
common known driver gene mutation, present in approxi-
mately 25% of adenocarcinomas [49]. Recently, two treat-
ments have emerged as promising for the patient with kRAS.
MAP kinase/ERK kinase (MEK) is downstream to signaling
from RAS, and selumetinib is an MEK inhibitor. A multicenter
international phase II trial compared treatment with do-
cetaxel andplacebowith treatment using docetaxel plus selu-
metinib for patients with KRAS mutation [50]. Patients
randomly assigned to selumetinib and docetaxel experienced
anumerically longerOS, a statistically significantly longer PFS,
and higher overall response rate than those treated with do-
cetaxel andplacebo. The rate of febrile neutropenia in thedo-
cetaxel plus selumetinib arm was 18.2% and in the docetaxel
plus placebo armswas 0%. ResultswithHSP-90 inhibitors also
look promising for patients with kRAS. A study of single-agent
ganetespib, an inhibitor of HSP-90 protein, included amolec-
ularly defined cohort of patients in whom NSCLC included a
KRASmutation[48].Theseresultswere followedbyarandom-
izedphase IIB/III studyofdocetaxel andganetespib compared
withdocetaxel alone, knownas theGanetespibAssessment in
Lung cAncer with docetaxel (GALAXY) study (NCT: 01348126)
[51]. The co-primary endpoints were PFS in patients with ele-
vated lactate dehydrogenase levels and mutant kRAS NSCLC.
An interimsafety analysis revealednoevidenceof benefit and
possible safety concerns in patients with non-adenocarci-
nomahistology, andconsequently, eligibilitywas restricted to
patients with adenocarcinoma histology. Preliminary results
revealed benefit from the combination therapy in patients
with adenocarcinoma histology, kRASmutation, and an ele-
vated lactatedehydrogenase level. These results areonly pre-
liminary, and a phase III trial is required.
MET is a receptor tyrosinekinase that is activatedbyhepa-
tocyte growth factor. MET expression is associated with ad-
verseprognosis andhasbeen implicated in resistance toEGFR
TKIs [52]. A randomized phase II study compared second-line
or third-line erlotinib with erlotinib plus onartuzumab, a
monoclonal antibody against theMET receptor [53]. Patients
were required to provide tissue, and a companion diagnostic
test was included in the trial design that determinedwhether
MET expression was present in tumors. The co-primary end-
pointswere PFS in the ITT patient population and inMET-pos-
itive patients. Patients whowereMET diagnostic positive and
assigned to erlotinib andonartuzumab therapy experienced a
significant improvement inPFSandOSwith theadditionofon-
artuzumab compared with those treated with erlotinib and
placebo. A phase III study comparing erlotinib with erlotinib
plusonartuzumab inpatientswhoareMETdiagnosticpositive
is underway (NCT01456325) [54].
Programmed death 1 (PD-1) protein is a T-cell co-inhibi-
tory receptor, andPD-L1 is oneof its ligands; disruptionof this
pathwayallows tumorcells toevade thehost immunesystem.
A phase I trial of the anti-PD-L1 antibody (BMS-936559) en-
rolled 207 patientswith advanced cancer; 75 patients had ad-
vancedNSCLC [55].OfpatientswithadvancedNSCLC, 49were
assessable for response, and of these, 5 had response. An-
other phase I trial of an anti-PD-1 antibody (BMS-936558) in-
cluded 76 assessable patients with NSCLC of whom 14
experienced an objective response. In an exploratory analysis
of 25 patients from this study with NSCLC and PD-L1-positive
tumors,9 respondedtothedrug [56].Phase III trialswithBMS-
936558 in the second-line setting are ongoing.
CONCLUSION
This article has summarized the current key clinical data needed
to inform clinical decision-making in second-line treatment of
NSCLC. In practice, clinical decisions arepersonalized to the indi-
vidual patient—their priorities, strengths, comorbidities, and
prior therapies. The goals of care in the second-line setting are
similar to those in the first-line setting: to maximize duration of
life,minimize toxicity, and improveQoL.
Whenatargetedmolecularoption isavailable, theauthors
strongly prefer that it be used. Therefore, for the patientwith
EGFRmutationwhohas not yet been treatedwith erlotinib or
gefitinib, or the patient with EML4/ALKwho has not yet been
treated with crizotinib, the clinical decision is easy. When an
experimental target such as kRAS or ROS1 is present, the au-
thors recommend participation in a clinical trial with an agent
that targets the relevant molecular pathway. Even when a
specific trial drug–target match is not available, clinical trials
for unselected patients should be strongly considered when
available. Trials incorporating agents targeting PD-1 and
PD-L1 are particularly promising.
Although targeted therapy is preferred when a target is
present, most patients are still treatedwith cytotoxic chemo-
therapy in the first lineand lackadrug-treatable target for sec-
ond-line therapy.For thepatientwithnonsquamoushistology
who is treatedwithanon-pemetrexeddoublet in the first line,
pemetrexed is recommended for second-line therapy be-
causeof its favorable sideeffectprofile anddata indicating su-
periorefficacy. For thepatientwith squamoushistologyor the
patient treated with pemetrexed in the first line (whether as
part of an initial cytotoxic doublet, as maintenance, or both),
docetaxel and erlotinib are the standard options. In the absence
of known EGFRmutation, existing data are not sufficient to de-
fineoneof thesemedicines as superior to theother. In our prac-
tice,wefavordocetaxel forhealthy, fit,motivatedpatientsbased
on superior PFS. However, we consider legitimate the choice of
erlotinib or gefitinib (where available) for patients who are less
fit, lesshealthy, or less tolerantof sideeffects.
Cytotoxic therapy is themostoftenused standard second-
line therapy for patients with EGFRmutationwho are treated
with erlotinib as first-line therapy or for patients with EML4/
ALK rearrangement treated with crizotinib as first-line ther-
apy. Therapy consists of whatever drugs would have been
otherwise used in the first line (typically carboplatin and pac-
litaxel with consideration of bevacizumab or carboplatin and
pemetrexedwith considerationofbevacizumab). Theauthors
favor enrollment in a promising second-line clinical trial that
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targets the mutation present prior to resorting to cytotoxic
therapy, if such a trial is available. In patients with oligopro-
gression on erlotinib or crizotinib, the authors consider abla-
tion of progressive sites followed by re-initiation of the
relevant targeted agentwhen possible.
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